Ductus Arteriosus, Patent [clinicaltrials_resource:8d0eedc2dd80425e45c4c4bfffb2f868]
Management of Patent Ductus in Premature Infants [clinicaltrials:NCT00000494]Reproduction and Survival After Cardiac Defect Repair [clinicaltrials:NCT00005190]clinicaltrials:NCT00009646New Management Strategy of PDA for VLBW Preterm Infants [clinicaltrials:NCT00239512]Comparing Ibuprofen And Indomethacin For The Treatment Of The Patent Ductus Arteriosus in Very Premature Babies [clinicaltrials:NCT00470743]Plasma B-Type Natriuretic Peptide Concentrations in Preterm Infants < 28 Weeks [clinicaltrials:NCT00528736]Plasma N-terminal proBNP Concentrations and Patent Ductus Arteriosus in Preterm Babies [clinicaltrials:NCT00725647]Urine NT-proBNP Levels and Echocardiographic Findings in Very Low Birth Weight (VLBW) Infants [clinicaltrials:NCT00799123]Patent Ductus Arteriosus (PDA) Screening Trial [clinicaltrials:NCT01031316]High-dose Ibuprofen for Patent Ductus Arteriosus (PDA) in Preterm Infant [clinicaltrials:NCT01243996]Changes in Renal and Splanchnic Oxygenation During Ibuprofen Treatment for Patent Ductus Arterious [clinicaltrials:NCT01251939]Paracetamol in Patent Ductus Arteriosus [clinicaltrials:NCT02422966]
condition [clinicaltrials_vocabulary:condition]
Management of Patent Ductus in Premature Infants [clinicaltrials:NCT00000494]Reproduction and Survival After Cardiac Defect Repair [clinicaltrials:NCT00005190]clinicaltrials:NCT00009646Nitric Oxide, Endothelin-1, and the Patency of Ductus Arteriosus in Preterm Infants [clinicaltrials:NCT00162903]Comparison of 2 Different Indomethacin Dosing Protocols to Treat Infants Delivered at <28 Weeks Gestation With a Persistent Patent Ductus Arteriosus [clinicaltrials:NCT00187447]Ibuprofen and Renal Function in Premature Infants [clinicaltrials:NCT00217191]New Management Strategy of PDA for VLBW Preterm Infants [clinicaltrials:NCT00239512]Safety and Efficacy Study of Ibuprofen l-Lysine Solution in Premature Infants for Treatment of PDA [clinicaltrials:NCT00440804]Comparing Ibuprofen And Indomethacin For The Treatment Of The Patent Ductus Arteriosus in Very Premature Babies [clinicaltrials:NCT00470743]Ibuprofen vs. Continuous Indomethacin in the Treatment of PDA [clinicaltrials:NCT00485160]The Use of B-Type Natriuretic Peptide (BNP) to Predict Closure of a Patent Ductus Arteriosus (PDA) in Premature Infants [clinicaltrials:NCT00500305]Plasma B-Type Natriuretic Peptide Concentrations in Preterm Infants < 28 Weeks [clinicaltrials:NCT00528736]Brain, Gut and Kidney Blood Flow During Medical Closure of PDA [clinicaltrials:NCT00554307]clinicaltrials:NCT00583596Treating the Resistant Patent Ductus Arteriosus (PDA) [clinicaltrials:NCT00616382]Comparative Study of Efficacy and Safety of Oral Ibuprofen and Intravenous Ibuprofen in Closure of Patent Ductus Arteriosus in Very Low Birth Weight Infants [clinicaltrials:NCT00642330]clinicaltrials:NCT00713700Plasma N-terminal proBNP Concentrations and Patent Ductus Arteriosus in Preterm Babies [clinicaltrials:NCT00725647]Feeding During Ibuprofen or Indomethacin Treatment of Preterm Infants [clinicaltrials:NCT00728117]An Escalating Dose Indomethacin for the Treatment of Persistent Patent Ductus Arteriosus (PDA) In Preterm Infants [clinicaltrials:NCT00750581]clinicaltrials:NCT00767039Timing for the Medical Treatment of Patent Ductus Arteriosus in Preterm Infants [clinicaltrials:NCT00795990]Urine NT-proBNP Levels and Echocardiographic Findings in Very Low Birth Weight (VLBW) Infants [clinicaltrials:NCT00799123]clinicaltrials:NCT00802685clinicaltrials:NCT00833365clinicaltrials:NCT00961753Impact of Maternal-infant Therapeutics on Safety, Mortality, and Disability [clinicaltrials:NCT01028183]Patent Ductus Arteriosus (PDA) Screening Trial [clinicaltrials:NCT01031316]Timing of Closure of Patent Foramen Ovale Following Birth [clinicaltrials:NCT01032785]Second Course of Therapy for Resistant Patent Ductus Arteriosus (PDA) [clinicaltrials:NCT01070745]High-dose Ibuprofen for Patent Ductus Arteriosus (PDA) in Preterm Infant [clinicaltrials:NCT01243996]Changes in Renal and Splanchnic Oxygenation During Ibuprofen Treatment for Patent Ductus Arterious [clinicaltrials:NCT01251939]Efficacy and Safety of Oral Versus Intravenous Ibuprofen for PDA Treatment in ELBW Infants [clinicaltrials:NCT01261117]Paracetamol and Patent Ductus Arteriosus (PDA) [clinicaltrials:NCT01291654]clinicaltrials:NCT01400737Influence of Treatment for Patent Ductus Arteriosus on Cerebral Oxygenation in Preterm Infants [clinicaltrials:NCT01428180]Safety and Effectiveness Study With a New PDA Occluder for Closure of Patent Ductus Arteriosus [clinicaltrials:NCT01479218]Do Elevated BNP Levels Predict Hemodynamically Significant PDAs [clinicaltrials:NCT01497054]Safety and Efficacy of Ibuprofen in Term Newborns With Patent Ductus Arteriosus (PDA) [clinicaltrials:NCT01511887]Oral Paracetamol Versus Oral Ibuprofen in Management of Patent Ductus Arteriosus in Preterm Infants: A Randomised Controlled Trial [clinicaltrials:NCT01536158]
condition browse [clinicaltrials_vocabulary:condition-browse]
Management of Patent Ductus in Premature Infants [clinicaltrials:NCT00000494]Reproduction and Survival After Cardiac Defect Repair [clinicaltrials:NCT00005190]clinicaltrials:NCT00009646Nitric Oxide, Endothelin-1, and the Patency of Ductus Arteriosus in Preterm Infants [clinicaltrials:NCT00162903]Comparison of 2 Different Indomethacin Dosing Protocols to Treat Infants Delivered at <28 Weeks Gestation With a Persistent Patent Ductus Arteriosus [clinicaltrials:NCT00187447]Ibuprofen and Renal Function in Premature Infants [clinicaltrials:NCT00217191]New Management Strategy of PDA for VLBW Preterm Infants [clinicaltrials:NCT00239512]Safety and Efficacy Study of Ibuprofen l-Lysine Solution in Premature Infants for Treatment of PDA [clinicaltrials:NCT00440804]Comparing Ibuprofen And Indomethacin For The Treatment Of The Patent Ductus Arteriosus in Very Premature Babies [clinicaltrials:NCT00470743]Ibuprofen vs. Continuous Indomethacin in the Treatment of PDA [clinicaltrials:NCT00485160]The Use of B-Type Natriuretic Peptide (BNP) to Predict Closure of a Patent Ductus Arteriosus (PDA) in Premature Infants [clinicaltrials:NCT00500305]Plasma B-Type Natriuretic Peptide Concentrations in Preterm Infants < 28 Weeks [clinicaltrials:NCT00528736]Brain, Gut and Kidney Blood Flow During Medical Closure of PDA [clinicaltrials:NCT00554307]clinicaltrials:NCT00583596Treating the Resistant Patent Ductus Arteriosus (PDA) [clinicaltrials:NCT00616382]Comparative Study of Efficacy and Safety of Oral Ibuprofen and Intravenous Ibuprofen in Closure of Patent Ductus Arteriosus in Very Low Birth Weight Infants [clinicaltrials:NCT00642330]clinicaltrials:NCT00713700Plasma N-terminal proBNP Concentrations and Patent Ductus Arteriosus in Preterm Babies [clinicaltrials:NCT00725647]Feeding During Ibuprofen or Indomethacin Treatment of Preterm Infants [clinicaltrials:NCT00728117]An Escalating Dose Indomethacin for the Treatment of Persistent Patent Ductus Arteriosus (PDA) In Preterm Infants [clinicaltrials:NCT00750581]clinicaltrials:NCT00767039Timing for the Medical Treatment of Patent Ductus Arteriosus in Preterm Infants [clinicaltrials:NCT00795990]Urine NT-proBNP Levels and Echocardiographic Findings in Very Low Birth Weight (VLBW) Infants [clinicaltrials:NCT00799123]clinicaltrials:NCT00802685clinicaltrials:NCT00833365clinicaltrials:NCT00961753Impact of Maternal-infant Therapeutics on Safety, Mortality, and Disability [clinicaltrials:NCT01028183]Patent Ductus Arteriosus (PDA) Screening Trial [clinicaltrials:NCT01031316]Timing of Closure of Patent Foramen Ovale Following Birth [clinicaltrials:NCT01032785]Second Course of Therapy for Resistant Patent Ductus Arteriosus (PDA) [clinicaltrials:NCT01070745]High-dose Ibuprofen for Patent Ductus Arteriosus (PDA) in Preterm Infant [clinicaltrials:NCT01243996]Changes in Renal and Splanchnic Oxygenation During Ibuprofen Treatment for Patent Ductus Arterious [clinicaltrials:NCT01251939]Efficacy and Safety of Oral Versus Intravenous Ibuprofen for PDA Treatment in ELBW Infants [clinicaltrials:NCT01261117]Paracetamol and Patent Ductus Arteriosus (PDA) [clinicaltrials:NCT01291654]clinicaltrials:NCT01400737Influence of Treatment for Patent Ductus Arteriosus on Cerebral Oxygenation in Preterm Infants [clinicaltrials:NCT01428180]Safety and Effectiveness Study With a New PDA Occluder for Closure of Patent Ductus Arteriosus [clinicaltrials:NCT01479218]Do Elevated BNP Levels Predict Hemodynamically Significant PDAs [clinicaltrials:NCT01497054]Safety and Efficacy of Ibuprofen in Term Newborns With Patent Ductus Arteriosus (PDA) [clinicaltrials:NCT01511887]Oral Paracetamol Versus Oral Ibuprofen in Management of Patent Ductus Arteriosus in Preterm Infants: A Randomised Controlled Trial [clinicaltrials:NCT01536158]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
Ductus Arteriosus, Patent [clinicaltrials_resource:8d0eedc2dd80425e45c4c4bfffb2f868]
Bio2RDF identifier
8d0eedc2dd80425e45c4c4bfffb2f868
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:8d0eedc2dd80425e45c4c4bfffb2f868
identifier
clinicaltrials_resource:8d0eedc2dd80425e45c4c4bfffb2f868
title
Ductus Arteriosus, Patent
@en
type
label
Ductus Arteriosus, Patent [clinicaltrials_resource:8d0eedc2dd80425e45c4c4bfffb2f868]
@en
Ductus Arteriosus, Patent